Recent developments in human immunodeficiency virus-1 latency research

J Gen Virol. 2013 May;94(Pt 5):917-932. doi: 10.1099/vir.0.049296-0. Epub 2013 Jan 30.

Abstract

Almost 30 years after its initial discovery, infection with the human immunodeficiency virus-1 (HIV-1) remains incurable and the virus persists due to reservoirs of latently infected CD4(+) memory T-cells and sanctuary sites within the infected individual where drug penetration is poor. Reactivating latent viruses has been a key strategy to completely eliminate the virus from the host, but many difficulties and unanswered questions remain. In this review, the latest developments in HIV-persistence and latency research are presented.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-HIV Agents / pharmacokinetics*
  • CD4-Positive T-Lymphocytes / virology
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV-1 / drug effects
  • HIV-1 / physiology*
  • Humans
  • Models, Biological
  • Virus Activation / drug effects
  • Virus Latency* / drug effects

Substances

  • Anti-HIV Agents